Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Operating Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Operating Margin for 7 consecutive years, with 15.29% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin rose 31743.0% to 15.29% in Q4 2025 year-over-year; TTM through Dec 2025 was 274.57%, a 37968.0% increase, with the full-year FY2025 number at 274.57%, up 37968.0% from a year prior.
  • Operating Margin was 15.29% for Q4 2025 at Beam Therapeutics, up from 1307.6% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 42.02% in Q4 2023 to a low of 3339550.0% in Q1 2021.
  • A 5-year average of 217166.87% and a median of 688.06% in 2024 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: tumbled -286696667bps in 2021, then surged 333864600bps in 2022.
  • Beam Therapeutics' Operating Margin stood at 124.31% in 2021, then tumbled by -257bps to 444.1% in 2022, then surged by 109bps to 42.02% in 2023, then tumbled by -892bps to 332.71% in 2024, then skyrocketed by 95bps to 15.29% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Operating Margin are 15.29% (Q4 2025), 1307.6% (Q3 2025), and 1419.22% (Q2 2025).